Edgewater Capital Partners, a lower middle-market private equity firm which has made previous investments in life Sciences and pharma services, has acquired GL Chemtec of Oakville, Ontario, a CRO which offers chemistry R&D and scale-up services to support API development, plus advanced materials for drug delivery, medical devices and other life science applications. No financial details were disclosed.